摘要
背景与目的微转移的检测对非小细胞肺癌的个体化治疗和指示预后具有重要意义。LUNX为近年新发现的人类肺组织特异性基因。本研究的目的是检测非小细胞肺癌(NSCLC)患者LUNXmRNA的表达情况,探讨其作为微转移检测分子标志物的可行性。方法选择初治的NSCLC患者62例,以肺部良性疾病10例与健康人10例作为对照组,采用实时荧光定量逆转录聚合酶链反应(FQ-RT-PCR)和普通RT-PCR技术,检测肺癌、良性病变肺组织、骨髓和外周血LUNXmRNA的表达。结果肺癌和良性病变肺组织中LUNXmRNA阳性表达率均为100%。肺良性病变组骨髓及外周血标本和健康对照组外周血标本中LUNXmRNA表达皆为阴性。62例NSCLC患者骨髓LUNXmRNA阳性表达率为38.7%(24/62),外周血LUNXmRNA阳性表达率为29.0%(18/62),至少一项阳性表达者占45.2%(28/62);骨髓LUNXmRNA阳性表达率随分期升高且有统计学意义(P=0.02),与病理类型、肿瘤分化程度无明显关系;外周血LUNXmRNA表达与病理分期、病理类型、肿瘤分化程度均无明显关系。NSCLC患者骨髓和外周血LUNXmRNA表达有相关性(P<0.001)。结论LUNXmRNA可作为检测NSCLC患者微转移的特异、敏感的分子标志物,可能有助于早期诊断肺癌转移,从而指导临床分期和治疗。
Background and objective There is important significance of micrometastasis for the individual treatment and prognosis of non-small cell lung cancer （NSCLC）. LUNX is a lung-specific gene found recently. The aim of this study is to detect LUNX mRNA expression in NSCLC patients in order to discuss the possibility of indicating lung cancer micrometastasis by LUNX. Methods Fluorescence quantitative reverse transcription-polymerase chain reaction （FQ-RT-PCR） and ordinary RT-PCR were used to detect LUNX mRNA in cancer tissues, bone marrow and peripheral blood from 62 patients with NSCLC. Lung tissue, bone marrow and peripheral blood from 10 patients with pulmonary benign diseases and peripheral blood from 10 healthy volunteers were served as controls. Results LUNX mRNA was expressed in all the lung tissues, either malignant or benign. No bone marrow and peripheral blood sample was positive for LUNX mRNA in controis. The positive detection rate of LUNX mRNA for NSCLC was 38.7% （24/62） in bone marrow, 29.0% （18/62） in peripheral blood, and 45.2% （28/62） in either. The positive rate of LUNX mRNA for NSCLC in bone marrow increased according to the stage of disease and there was a statistical significance （P=0.02）, and there was a correlation between bone marrow and peripheral blood expression in NSCLC （P〈0. 001）. Conclusion LUNX mRNA is an efficient indicating factor on sensitivity and specificity to detect early haematogenous dissemination of cancer cells for patients with NSCLC. This method may lead to an earlier diagnosis of metastasis for lung cancer and help to evaluate the cancer more correctly and make the best treatment plan.
出处
《中国肺癌杂志》
CAS
2006年第6期506-510,共5页
Chinese Journal of Lung Cancer
基金
天津市自然科学基金(No.023616711)资助~~
